Drug Description in Trials / DrugBank / KEGG DRUG /

  

Search results

No. 薬物名（臨床試験情報から抽出） DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY 指定難病告示番号
111C-CSar----2件: 93, 94
23108006977----1件: 94
3[18F]FP-R01-MG-F2----2件: 85, 94
4A3907----1件: 94
5Acetylcysteine1件: Acetylcysteine1件: D00221 --21件: 6, 13, 19, 20, 21, 49, 51, 53, 58, 63, 85, 90, 94, 111, 164, 193, 233, 296, 298, 299, 337
6ACIDO DEOSSICOLICO----1件: 94
7Acido Obeticolico----2件: 93, 94
8All-trans retinoic acid1件: Tretinoin1件: D00094 3件: PML,
RARA,
RARB 💬		12件: Acute myeloid leukemia, Endocytosis, Estrogen signaling pathway, Gastric cancer, Herpes simplex virus 1 infection, Influenza A, Non-small cell lung cancer, Pathways in cancer, Small cell lung cancer, Th17 cell differentiation, Transcriptional misregulation in cancer, Ubiquitin mediated proteolysis 💬1件: 94
9ATRA1件: Tretinoin1件: D00094 3件: PML,
RARA,
RARB 💬		12件: Acute myeloid leukemia, Endocytosis, Estrogen signaling pathway, Gastric cancer, Herpes simplex virus 1 infection, Influenza A, Non-small cell lung cancer, Pathways in cancer, Small cell lung cancer, Th17 cell differentiation, Transcriptional misregulation in cancer, Ubiquitin mediated proteolysis 💬2件: 63, 94
10Azathioprine1件: Azathioprine1件: D00238 --21件: 6, 11, 13, 19, 35, 42, 43, 44, 45, 46, 49, 63, 65, 66, 85, 93, 94, 95, 96, 97, 162
11AZT----2件: 94, 265
12Befizal----1件: 94
13BEFIZAL L.P. 400 mg, comprimé enrobé à libération prolongée----1件: 94
14Bexotegrast----1件: 94
15Bezafibrate1件: Bezafibrate1件: D01366 1件: PPARA 💬10件: Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬7件: 20, 93, 94, 160, 296, 316, 324
16Bezafibrate (400mg) in addition to standard 15-20 mg/kg/jour UDCA therapy2件: Bezafibrate,
Ursodeoxycholic acid		2件: D00734 ,
D01366 		2件: NR1H4,
PPARA 💬		11件: Adipocytokine signaling pathway, Alcoholic liver disease, Bile secretion, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬1件: 94
17Bezalip----3件: 93, 94, 160
18BTT1023----1件: 94
19BTT1023 IV Infusion 20 mg/mL, 5 mL Drug Product----1件: 94
20BUDESONIDE1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬9件: 66, 93, 94, 95, 96, 97, 98, 228, 299
21C10AB02----1件: 94
22Calcium1件: Calcium---27件: 6, 13, 19, 46, 49, 51, 53, 56, 68, 75, 79, 84, 93, 94, 95, 96, 97, 156, 214, 215, 222, 224, 235, 265, 274, 298, 299
23Cenicriviroc1件: Cenicriviroc1件: D09878 2件: CCR2,
CCR5 💬		11件: Chemokine signaling pathway, Cytokine-cytokine receptor interaction, Endocytosis, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Toxoplasmosis, Viral carcinogenesis, Viral life cycle - HIV-1, Viral protein interaction with cytokine and cytokine receptor, Virion - Human immunodeficiency virus 💬1件: 94
24Cenicriviroc 150 mg1件: Cenicriviroc1件: D09878 2件: CCR2,
CCR5 💬		11件: Chemokine signaling pathway, Cytokine-cytokine receptor interaction, Endocytosis, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Toxoplasmosis, Viral carcinogenesis, Viral life cycle - HIV-1, Viral protein interaction with cytokine and cytokine receptor, Virion - Human immunodeficiency virus 💬1件: 94
25CILO----1件: 94
26Cilofexor1件: Cilofexor---2件: 93, 94
27Cis-4-Hydroxy-L-Proline1件: Proline1件: D00035 --1件: 94
28CLADRIBINE1件: Cladribine1件: D01370 1件: RRM1 💬6件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Nucleotide metabolism, Purine metabolism, Pyrimidine metabolism 💬3件: 11, 13, 94
29CM-101----1件: 94
30CS0159----2件: 93, 94
31Curcumin1件: Curcumin---10件: 2, 13, 46, 67, 74, 94, 96, 97, 139, 299
32DHA----8件: 6, 46, 48, 49, 94, 113, 299, 301
33Docosahexaenoic acid1件: Doconexent---7件: 6, 49, 90, 94, 240, 299, 301
34Docosahexaenoic Acid (DHA)1件: Doconexent---3件: 6, 94, 299
35DUR-928----1件: 94
36ELAFIBRANOR1件: Elafibranor1件: D11208 1件: PPARA 💬10件: Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬2件: 93, 94
37Elafibranor 120 mg1件: Elafibranor1件: D11208 1件: PPARA 💬10件: Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬2件: 93, 94
38Elafibranor 80 mg1件: Elafibranor1件: D11208 1件: PPARA 💬10件: Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬2件: 93, 94
39Engineered recombinant human FGF19----1件: 94
40Entyvio1件: Vedolizumab1件: D08083 2件: ITGA4,
ITGB7 💬		15件: Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬3件: 94, 96, 97
41EP547----2件: 93, 94
42Erlotinib1件: Erlotinib1件: D07907 1件: EGFR 💬48件: Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Coronavirus disease - COVID-19, Cushing syndrome, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endocytosis, Endometrial cancer, Epithelial cell signaling in Helicobacter pylori infection, ErbB signaling pathway, Estrogen signaling pathway, Focal adhesion, FoxO signaling pathway, Gap junction, Gastric cancer, Glioma, GnRH signaling pathway, HIF-1 signaling pathway, Hepatitis C, Hepatocellular carcinoma, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, Non-small cell lung cancer, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Shigellosis 💬1件: 94
43Erlotinib (Tarceva)1件: Erlotinib1件: D07907 1件: EGFR 💬48件: Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Coronavirus disease - COVID-19, Cushing syndrome, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endocytosis, Endometrial cancer, Epithelial cell signaling in Helicobacter pylori infection, ErbB signaling pathway, Estrogen signaling pathway, Focal adhesion, FoxO signaling pathway, Gap junction, Gastric cancer, Glioma, GnRH signaling pathway, HIF-1 signaling pathway, Hepatitis C, Hepatocellular carcinoma, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, Non-small cell lung cancer, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Shigellosis 💬1件: 94
44Fecal microbiota transplantation----5件: 2, 66, 94, 96, 97
45Fenofibrate1件: Fenofibrate1件: D00565 1件: PPARA 💬10件: Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬6件: 8, 79, 93, 94, 97, 265
46Fluimucil----4件: 85, 94, 193, 298
47FLUIMUCIL*20CPR EFF 600MG----2件: 94, 298
48Genetic analysis----6件: 34, 85, 90, 93, 94, 96
49GFT505----2件: 93, 94
50Gluten-free diet----1件: 94
51GS-66241件: Simtuzumab---2件: 85, 94
52GS-9674----2件: 93, 94
53HTD1801----1件: 94
54Humanised IgG1 monoclonal antibody against human eotaxin-2----1件: 94
55Hymecromone1件: Hymecromone1件: D00170 --1件: 94
56ICG----2件: 93, 94
57INT-747, OCA----2件: 93, 94
58IPN60190----1件: 94
59LUM001----4件: 93, 94, 297, 338
60MBX-8025----3件: 79, 93, 94
61METRONIDAZOLE1件: Metronidazole1件: D00409 --7件: 46, 51, 63, 94, 96, 97, 291
62Minocycline1件: Minocycline1件: D05045 --13件: 2, 6, 8, 13, 46, 85, 90, 94, 162, 201, 206, 280, 299
63Mitomycin1件: Mitomycin1件: D00208 --2件: 94, 329
64Mitomycin C1件: Mitomycin1件: D00208 --1件: 94
65Mizoribine1件: Mizoribine1件: D01392 2件: IMPDH1,
IMPDH2 💬		4件: Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬8件: 46, 49, 51, 53, 66, 94, 222, 224
66MLN0002----3件: 94, 96, 97
67NGM282----2件: 93, 94
68Normal Saline----18件: 6, 13, 17, 22, 36, 46, 49, 60, 70, 94, 96, 210, 211, 226, 271, 276, 296, 299
69Norucholic acid1件: norUrsodeoxycholic acid---2件: 93, 94
70NorUDCA----1件: 94
71NorUDCA (Norursodeoxycholic acid)1件: norUrsodeoxycholic acid---1件: 94
72NorUrsodeoxycholic Acid1件: norUrsodeoxycholic acid---1件: 94
73Norursodeoxycholic acid, NCA1件: norUrsodeoxycholic acid---1件: 94
74OCA----2件: 94, 296
75OCA 1,5 mg----1件: 94
76OCA 5 mg----1件: 94
77Oral all-trans retinoic acid (ATRA)1件: Tretinoin1件: D00094 3件: PML,
RARA,
RARB 💬		12件: Acute myeloid leukemia, Endocytosis, Estrogen signaling pathway, Gastric cancer, Herpes simplex virus 1 infection, Influenza A, Non-small cell lung cancer, Pathways in cancer, Small cell lung cancer, Th17 cell differentiation, Transcriptional misregulation in cancer, Ubiquitin mediated proteolysis 💬1件: 94
78Oral Vancomycin1件: Vancomycin1件: D00212 --2件: 94, 296
79Orbcel-C1件: Allogenic Donor CD362-enriched Human Umbilical Cord-derived Mesenchymal Stem Cells---2件: 94, 95
80PHENYLBUTYRATE1件: Phenylbutyric acid---12件: 2, 3, 6, 8, 15, 93, 94, 244, 251, 297, 299, 338
81PLN-748091件: PLN-74809---2件: 85, 94
82Potassium1件: Potassium1件: D08403 --13件: 36, 46, 66, 67, 88, 93, 94, 98, 115, 167, 179, 215, 235
83Probiotics----5件: 6, 94, 96, 97, 291
84Proline1件: Proline1件: D00035 --2件: 94, 97
85Rec-h-FGF19----1件: 94
86Retinoic acid1件: Tretinoin1件: D00094 3件: PML,
RARA,
RARB 💬		12件: Acute myeloid leukemia, Endocytosis, Estrogen signaling pathway, Gastric cancer, Herpes simplex virus 1 infection, Influenza A, Non-small cell lung cancer, Pathways in cancer, Small cell lung cancer, Th17 cell differentiation, Transcriptional misregulation in cancer, Ubiquitin mediated proteolysis 💬2件: 94, 231
87RITUXIMAB1件: Rituximab1件: D02994 1件: MS4A1 💬1件: Hematopoietic cell lineage 💬48件: 11, 13, 14, 19, 26, 35, 36, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 53, 55, 56, 60, 61, 63, 64, 65, 66, 83, 84, 85, 86, 93, 94, 96, 97, 162, 222, 229, 256, 271, 274, 283, 284, 285, 288, 296, 300, 331
88SELADELPAR1件: Seladelpar1件: D11256 1件: PPARG 💬11件: AMPK signaling pathway, Huntington disease, Lipid and atherosclerosis, Longevity regulating pathway, Non-alcoholic fatty liver disease, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer 💬2件: 93, 94
89Simtuzimab----1件: 94
90Simtuzumab1件: Simtuzumab---2件: 85, 94
91Simvastatin1件: Simvastatin1件: D00434 1件: HMGCR 💬4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬21件: 6, 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 160, 162, 195, 265, 288, 298, 299, 310
92Simvastatin 40mg1件: Simvastatin1件: D00434 1件: HMGCR 💬4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬1件: 94
93SULFASALAZINE1件: Sulfasalazine1件: D00448 --6件: 46, 86, 94, 107, 270, 271
94TBC----3件: 85, 94, 96
95Thalidomide1件: Thalidomide1件: D00754 1件: TNF 💬67件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬20件: 2, 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331
96UCMSC----2件: 51, 94
97UDCA1件: Ursodeoxycholic acid1件: D00734 1件: NR1H4 💬1件: Bile secretion 💬6件: 46, 67, 93, 94, 97, 296
98Ursodeoxycholic acid1件: Ursodeoxycholic acid1件: D00734 1件: NR1H4 💬1件: Bile secretion 💬10件: 6, 46, 67, 84, 93, 94, 95, 96, 97, 296
99Ursodeoxycholic acid (UDCA)1件: Ursodeoxycholic acid1件: D00734 1件: NR1H4 💬1件: Bile secretion 💬1件: 94
100Ursofalk1件: Ursodeoxycholic acid1件: D00734 1件: NR1H4 💬1件: Bile secretion 💬4件: 93, 94, 96, 97
101Ursolic acid1件: Ursolic acid---1件: 94
102Vancomycin1件: Vancomycin1件: D00212 --8件: 13, 46, 70, 94, 96, 97, 296, 299
103VEDOLIZUMAB1件: Vedolizumab1件: D08083 2件: ITGA4,
ITGB7 💬		15件: Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬3件: 94, 96, 97
104Vedolizumab IV1件: Vedolizumab1件: D08083 2件: ITGA4,
ITGB7 💬		15件: Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬3件: 94, 96, 97
105Vidofludimus1件: Vidofludimus---5件: 13, 46, 94, 96, 97
106VIDOFLUDIMUS CALCIUM2件: Calcium,
Vidofludimus		---4件: 13, 94, 96, 97
107Volixibat1件: Volixibat1件: D11007 --2件: 93, 94
108Volixibat (formely SHP626, LUM002 or SAR548304B)1件: Volixibat1件: D11007 --1件: 94
109Volixibat potassium2件: Potassium,
Volixibat		2件: D08403 ,
D11007 		--2件: 93, 94
110Xifaxan1件: Rifaximin1件: D02554 --2件: 65, 94